• Merck & Co. Inc., of Whitehouse Station, N.J., said the FDA has accepted for standard review its new drug application for its investigational anti-thrombotic medicine, vorapaxar for the secondary prevention of cardiovascular events in patients with a history of heart attack and no history of stroke or transient ischemic attack.